We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A sponsor of drug-device combination trials failed to submit IND applications, get signed investigator statements and select monitors before beginning the studies, and it did not maintain drug disposition records once the trials were under way, according to an FDA warning letter.